Indivior Patent-Cliff Exposure & CMS Drug Spending Portfolio

Indivior (North Chesterfield, VA): 4 reconciled FDA prescription therapies (58.0% 2025 to 2030 cliff risk), $1.66B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNorth Chesterfield, VA
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure58.0%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$1.66B
2024 Medicare Part D Spend$169.5M
2024 Medicaid Spend$1.49B
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel